Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sunmax Biotechnology Co's share price is NT$376.50.
Sunmax Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$37.16. Hence, Sunmax Biotechnology Co's PS Ratio for today is 10.13.
The historical rank and industry rank for Sunmax Biotechnology Co's PS Ratio or its related term are showing as below:
ROCO:4728'
s PS Ratio Range Over the Past 10 Years
Min: 3.63 Med: 8.55 Max: 24.48
Current: 10.13
During the past 13 years, Sunmax Biotechnology Co's highest PS Ratio was 24.48. The lowest was 3.63. And the median was 8.55.
ROCO:4728's PS Ratio is ranked worse than 52.47% of 930
companies
in the Biotechnology industry
Industry Median: 9.35
vs ROCO:4728: 10.13
During the past 12 months, the average Revenue per Share Growth Rate of Sunmax Biotechnology Co was 11.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 16.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 33.80% per year.
During the past 13 years, Sunmax Biotechnology Co's highest 3-Year average Revenue per Share Growth Rate was 64.60% per year. The lowest was -9.80% per year. And the median was 17.55% per year.
Back to Basics: PS Ratio
Sunmax Biotechnology Co (ROCO:4728) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4728 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Sunmax Biotechnology Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunmax Biotechnology Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sunmax Biotechnology Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Sunmax Biotechnology Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Sunmax Biotechnology Co's Share Price of today is NT$376.50. Sunmax Biotechnology Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$37.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Sunmax Biotechnology Co (ROCO:4728) has a PS Ratio of 10.13 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sunmax Biotechnology Co and its competitors. This is 18% above median its historical median of 8.55. Over the past decade, Sunmax Biotechnology Co's PS Ratio has ranged from 3.63 to 24.48. According to the industry distribution chart, Sunmax Biotechnology Co ranks #488 out of 930 companies in the Biotechnology industry, placing it in the top 52.5%.
Is Sunmax Biotechnology Co's PS Ratio too high?
Sunmax Biotechnology Co's current PS Ratio of 10.13 is 18% above median its 10-year median of 8.55. Over the past 10 years, this metric has ranged from a low of 3.63 to a high of 24.48. The Biotechnology industry median PS Ratio is 9.35. Sunmax Biotechnology Co's value of 10.13 is 8.3% above this industry median. Based on the distribution chart, Sunmax Biotechnology Co ranks #488 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sunmax Biotechnology Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunmax Biotechnology Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunmax Biotechnology Co ranks #488 out of 930 companies for PS Ratio. This places Sunmax Biotechnology Co in the lower half of its industry. The industry median PS Ratio is 9.35. Sunmax Biotechnology Co's value of 10.13 is 8.3% above this benchmark. Historically, Sunmax Biotechnology Co's own PS Ratio has ranged from 3.63 to 24.48 over the past decade. While the company's 10-year median is 8.55 vs. the industry median of 9.35, Sunmax Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.35, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunmax Biotechnology Co's current PS Ratio of 10.13 is 8.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Sunmax Biotechnology Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunmax Biotechnology Co's current PS Ratio is 10.13, which is 18% above median its own 10-year median of 8.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunmax Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sunmax Biotechnology Co (ROCO:4728) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$442.26, compared to a current price of NT$376.50 — trading 14.9% below its estimated fair value. The current PS Ratio is 10.13, which is 18% above median its 10-year median of 8.55 and 8.3% above the Biotechnology industry median of 9.35. Sunmax Biotechnology Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Sunmax Biotechnology Co (ROCO:4728), the current PS Ratio is 10.13 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunmax Biotechnology Co (ROCO:4728) Overvalued in 2026?
Based on GuruFocus' analysis, Sunmax Biotechnology Co stock appears to be undervalued.
The current stock price of NT$376.50 is trading 14.9% below its estimated GF Value™ of NT$442.26.
GuruFocus considers Sunmax Biotechnology Co to be Modestly Undervalued.
Key valuation signals for ROCO:4728:
PS Ratio: 10.13 (18% above median its 10-year median of 8.55)
GF Value™: NT$442.26 vs. price of NT$376.50 (14.9% below fair value)
Industry Position: 8.3% above the Biotechnology median (#488 of 930)
No single metric tells the full story. See the ROCO:4728 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
91GF Score
Get the complete analysis for ROCO:4728
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4728 has been successfully added to your 
